- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer
- Interventions
- POL6326
- Drug
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Kansas City, Kansas • St Louis, Missouri • Lebanon, New Hampshire + 2 more
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
- Interventions
- eribulin mesylate, carboplatin, biopsy
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- INT230-6, Eribulin, Trabectedin, Pazopanib
- Drug
- Lead sponsor
- Intensity Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Anakinra plus Standard of Care
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm, Malignant Solid Neoplasm, Malignant Spermatic Cord Neoplasm
- Interventions
- Eribulin Mesylate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
- Drug · Radiation · Other + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2033
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
- Interventions
- Eribulin, Cyclophosphamide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more
- Conditions
- Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
- Interventions
- Eribulin, Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 543 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
- Conditions
- Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Interventions
- Eribulin Mesylate, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 12
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Bozeman, Montana + 7 more
- Conditions
- Breast Cancer
- Interventions
- Eribulin Mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Columbia, Maryland • Omaha, Nebraska + 8 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pleasant Hill, California • San Diego, California + 10 more
- Conditions
- Metastasis, Breast Cancer
- Interventions
- NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 16 more
- Conditions
- Estrogen Receptor Positive Tumor, Breast Cancer
- Interventions
- eribulin mesylate, capecitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Orlando, Florida • Marietta, Georgia + 16 more
- Conditions
- Breast Neoplasms
- Interventions
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 71
- States / cities
- Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more
- Conditions
- Metastatic Breast Cancer, Locally Recurrent Breast Cancer
- Interventions
- Eribulin, Balixafortide
- Drug
- Lead sponsor
- Spexis AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 28
- States / cities
- Fresno, California • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
- Interventions
- ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
- Drug
- Lead sponsor
- Enliven Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Plantation, Florida • St Louis, Missouri • Fairfax, Virginia
- Conditions
- Breast Cancer
- Interventions
- AEZS-108, SCCC, Dexamethasone
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- E7389 28 Day Cycle, E7389 21 Day Cycle
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 13
- States / cities
- Gilroy, California • Ocala, Florida • Baltimore, Maryland + 10 more
- Conditions
- Head and Neck Cancer, Colon Cancer
- Interventions
- Head and neck, Colon- Closed as of May 2014
- Drug
- Lead sponsor
- howard safran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- The Bronx, New York • Pawtucket, Rhode Island • Providence, Rhode Island
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
- Interventions
- SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
- Biological · Drug
- Lead sponsor
- BriaCell Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- (vic-)trastuzumab duocarmazine, Physician's choice
- Drug
- Lead sponsor
- Byondis B.V.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Tucson, Arizona • San Diego, California + 17 more